Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP: CYDY )

0.3350 -0.0050 (-1.47%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 646,412
Open 0.3393
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3400
Today's Range 0.3200 - 0.3599
52wk Range 0.2311 - 2.830
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
-66.50%
-66.50%
1 Month
+33.31%
+33.31%
3 Month
-36.79%
-36.79%
6 Month
-72.87%
-72.87%
1 Year
-83.58%
-83.58%

More News

Read More
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
Via Benzinga
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
From CytoDyn Inc.
Via Business Wire
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
From CytoDyn Inc.
Via Business Wire
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
From CytoDyn Inc.
Via Business Wire
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
From CytoDyn Inc.
Via Business Wire
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Via Benzinga
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
From CytoDyn Inc.
Via Business Wire
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
From CytoDyn Inc.
Via Business Wire
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
From CytoDyn Inc.
Via Business Wire
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
From CytoDyn Inc.
Via Business Wire
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
From CytoDyn Inc.
Via Business Wire
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
From CytoDyn Inc.
Via Business Wire
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
From CytoDyn Inc.
Via Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
From CytoDyn Inc.
Via Business Wire
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
From CytoDyn Inc.
Via Business Wire
Group of CytoDyn Stockholders Comments on Delaware Court Decision
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
From CytoDyn Inc.
Via Business Wire
These OTC Markets Securities had the Most Trading Activity in September
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.